On June 11, XtalPi Holdings declined 5.02% in regular trading, trading at 6.62 HKD/share, with trading volume of approximately 177 million HKD.

The decline comes as valuation pressure continues to weigh on shares despite a series of positive announcements. On June 9, the company disclosed a strategic AI drug discovery partnership with a leading international biopharmaceutical firm worth over 400 million USD, targeting a GPCR oral drug candidate. Simultaneously, the board approved a 100 million USD share buyback program. However, market reaction has been muted — the partnership news only triggered a brief 4% opening gap before shares reversed lower.

Although XtalPi reported revenue of 803 million RMB for fiscal year 2025, up 201.2% year-over-year, and achieved its first annual profit with adjusted net income of 258 million RMB, its dynamic price-to-earnings ratio remains elevated at approximately 212x. The broader Life Sciences Tools and Services sector also faced selling pressure, with WuXi XDC down 5.56%, Insilico Medicine down 6.28%, and WuXi Biologics down 2.22%, reflecting weak sector sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)